Polpharma Biologics Growth Timeline
Acquisition of Polpharma by Jerzy Starak, a committed and visionary entrepreneur who still controls Polpharma and Polpharma Biologics today.
Polpharma, a leading pharmaceutical company in Poland and the central European region, launches biotech operations – 12 employees.
Biotechnology R&D centre established in Gdańsk - 29 employees.
Bioeq established - joint venture with Atos on the co-development of Ranibizumab - 47 employees.
Acquisition of Bioceros BV, an early stage biotech development company in Utrecht, Netherlands – 96 employees.
Rapid development of the biotechnology R&D centre in Gdańsk – 330 employees.
Creation of an independent Polpharma Biologics (spin-off from Polpharma) – 500 employees. Out-licensing deal for Natalizumab with Sandoz. Out-licensing deal for Ranibizumab with Coherus.
Duchnice manufacturing and development site joins Polpharma Biologics – 700+ employees.
Bioeq – spółka joint venture Grupy Polpharma Biologics, zawiera umowę z Teva na komercjalizację leku biopodobnego do ranibizumabu na rynkach europejskich oraz w Kanadzie